AGC Biologics announces new partnership with Altheia Science

KUALA LUMPUR, July 29 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organisation, has announced a new partnership with gene therapy company, Altheia Science.

“We are pleased that Altheia Science has placed their trust in our cell therapy and viral vector services, and our Milan site, at this important stage in their product’s lifecycle,” said AGC Biologics chief business officer JB Agnus in a statement.

Through this partnership, Altheia Science will advance its development of autoimmunity treatments.

“The AGC Biologics Milan site has a long-standing expertise in successfully developing stem cell-based gene therapies, from clinical testing up to commercialisation,” said Altheia Science chief executive officer Paolo Rizzardi.

“We believe this partnership is key in supporting our gene therapy programmes and making these innovative therapies available to patients.”

The AGC Biologics Milan facility has one of the strongest development and manufacturing track records in the global cell and gene industry, working with virtually any cell type and lentiviral, retroviral and adeno‐associated viral vectors.

AGC Biologics’ cell therapy services and viral vector capabilities leverage the latest technology and processes, including proprietary platforms developed to address the evolving advanced therapies industry.

More details at www.agcbio.com.

-- BERNAMA